Author of

• 28971

  +

  Lunch & Poster Display session (ID 58)

  • Event: ELCC 2019
  • Type: Poster Display session
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 4/11/2019, 12:30 - 13:00, Hall 1

  • 29025

    +

    62P - External validation of a survival score for limited stage small cell lung cancer treated with chemoradiotherapy (ID 570)

    12:30 - 13:00  |  Author(s): Reem Abdo
    • Abstract
    • Slides

    Background
    

    In 2016, a survival score for limited stage small cell lung cancer (LS-SCLC) patients was developed to characterize prognostic sub-groups who underwent multimodal treatment. Herein, we validate the score in an independent external patient cohort.

    a9ded1e5ce5d75814730bb4caaf49419 Methods
    

    We reviewed the medical charts of 78 LS-SCLC patients treated with CRT at our institution. The survival score was calculated by independent prognostic factors: gender, Karnofsky performance status (50-70% vs. 80-100%), Tumor sub-stage (very limited vs. limited disease) and hemoglobin level before the start of radiation (<12 g/dl vs. ≥12 g/dl). Scoring points were derived from 2-year survival rates divided by 10 and the individual values for each prognostic factor were tallied. Three risk subgroups were defined (high, intermediate vs. low-risk: 9-13, 14-18 vs.19-26 points).

    20c51b5f4e9aeb5334c90ff072e6f928 Results
    

    Median overall survival in the validation cohort was 17 months (range: 1-123months). The 2-year survival rates were 0% in the high, 35% in the intermediate and 43% in the low-risk subgroup, respectively (p = 0.018). The difference in 2-year survival between the high and intermediate risk subgroups was significant (p = 0.007), whereas the 2yr-OS between the intermediate and low risk was not (p = 0.602). After stratification for the concurrent treatment mode, 2-year survival rates were 0% in the high, 60% in the intermediate and 58% in the low-risk subgroups, respectively (p = 0.004).

    fd69c5cf902969e6fb71d043085ddee6 Conclusions
    

    The survival score was reproducible to estimate 2-year survival rates of patients with LS-SCLC, especially in the high and intermediate-risk subgroups. In order to better characterize the prognostic difference between intermediate and low-risk patients, the scoring system needs further optimization.

    b651e8a99c4375feb982b7c2cad376e9 Legal entity responsible for the study
    

    The authors.

    213f68309caaa4ccc14d5f99789640ad Funding
    

    Has not received any funding.

    682889d0a1d3b50267a69346a750433d Disclosure
    

    All authors have declared no conflicts of interest.

    cffcb1a185b2d7d5c44e9dc785b6bb25

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.